Medmira (MIR) AI Stock Analysis

• Market Cap: C$48.84M
• Dividend Yield: N/A
• Average Volume (3M): 94.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -41.70%
• EPS Growth: -35.42%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 697,666,140
• 10 Day Avg. Volume: 79,718
• 30 Day Avg. Volume: 94,909
• PEG Ratio: -0.35
• Price to Book (P/B): -2.47
• Price to Sales (P/S): 232.06
• P/FCF Ratio: -17.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: C$0.07 ▼(-7.14% Downside)

The score is primarily held down by weak financial performance—persistent losses, continued cash burn, and a highly stressed balance sheet with negative equity and elevated leverage. Technicals add pressure with the stock trading below major moving averages and a negative MACD, while valuation provides limited support due to negative earnings and no dividend yield provided.

Positive Factors

Market Demand

Growing demand for rapid diagnostic tests in emerging markets supports long-term revenue potential, aligning with global health trends.

Product Offering

Proprietary rapid test technologies offer a competitive edge by providing reliable, easy-to-use solutions, enhancing market position.

Revenue Streams

Diverse revenue streams from sales, licensing, and partnerships enhance financial stability and market reach, supporting growth.

Negative Factors

Financial Performance

Negative profitability and declining revenues indicate structural financial challenges, impacting long-term sustainability.

Balance Sheet Health

Negative equity and high financial risk limit financial flexibility, posing long-term challenges to operational stability.

Cash Flow Challenges

Persistent negative cash flows highlight cash generation issues, constraining investment and growth opportunities.

Medmira Business Overview & Revenue Model

Company Description

Medmira Inc. (MIR) is a Canadian biotechnology company primarily focused on the development and commercialization of rapid diagnostic tests for various infectious diseases. The company operates in the healthcare sector, specializing in point-of-care testing solutions that enable quick and accurate diagnosis of conditions such as HIV, Hepatitis, and other sexually transmitted infections. Medmira's core product offerings include its proprietary rapid test technologies, which are designed to provide reliable results with minimal equipment and training, catering to both clinical and non-clinical settings worldwide.

How the Company Makes Money

Medmira generates revenue through the sale of its rapid diagnostic tests to healthcare providers, laboratories, and distributors across multiple regions. The company has established key revenue streams that include direct sales of its products, licensing agreements for its technologies, and partnerships with other healthcare organizations to expand its market reach. Additionally, Medmira benefits from contracts with government agencies and non-governmental organizations (NGOs) that require diagnostic testing solutions in various public health initiatives. The company's focus on innovation and the increasing demand for rapid diagnostic solutions in emerging markets further contribute to its financial performance.

Medmira Financial Statement Overview

Summary

Medmira's financial performance is severely challenged, with declining revenues, negative profitability margins, and a weak balance sheet characterized by negative equity. Cash flow issues further exacerbate the situation, with negative operating and free cash flows.

Income Statement

Medmira's income statement reveals significant challenges. The company has experienced declining revenues over the past few years, with a negative revenue growth rate of -5.42% in the most recent year. Gross profit margins have been negative, indicating that the cost of goods sold exceeds revenue. Net profit margins are also deeply negative, reflecting ongoing losses. EBIT and EBITDA margins are negative, highlighting operational inefficiencies and a lack of profitability.

Balance Sheet

The balance sheet shows a concerning financial structure with negative stockholders' equity, indicating that liabilities exceed assets. The debt-to-equity ratio is negative due to the negative equity, suggesting high financial risk. Return on equity is negative, further emphasizing the company's inability to generate profit from its equity base. The equity ratio is also negative, pointing to a weak financial position.

Cash Flow

Cash flow analysis indicates persistent cash flow challenges. Operating cash flow and free cash flow are both negative, with a declining free cash flow growth rate of -23.86%. The operating cash flow to net income ratio is negative, reflecting insufficient cash generation relative to net losses. The free cash flow to net income ratio is positive, indicating that free cash flow is less negative than net income, but this is due to both metrics being negative.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	240.51K	412.57K	432.53K	952.13K	2.14M
Gross Profit	-990.25K	226.49K	-434.91K	304.03K	1.72M
EBITDA	-3.13M	-2.13M	-1.58M	-1.07M	185.30K
Net Income	-4.52M	-3.33M	-2.68M	-1.83M	-675.80K
Balance Sheet
Total Assets	3.68M	6.07M	3.65M	3.83M	3.89M
Cash, Cash Equivalents and Short-Term Investments	14.91K	2.10M	13.18K	33.46K	-2.30M
Total Debt	10.71M	9.56M	9.27M	8.30M	11.54M
Total Liabilities	26.24M	24.11M	18.68M	16.19M	19.61M
Stockholders Equity	-22.56M	-18.04M	-15.03M	-12.36M	-15.72M
Cash Flow
Free Cash Flow	-3.15M	-3.68M	-1.27M	-1.95M	-541.19K
Operating Cash Flow	-3.15M	-2.94M	-1.27M	-1.88M	-504.64K
Investing Cash Flow	-7.47K	-742.53K	-1.27K	-69.72K	-36.55K
Financing Cash Flow	1.07M	5.77M	1.25M	1.99M	139.32K

Medmira Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Neutral. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.28 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MIR.

Medmira Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	53 Neutral	C$47.71M	23.17	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBX	49 Neutral	C$33.31M	-15.19	-8.01%	―	-26.81%	-161.24%
DTC	45 Neutral	C$32.84M	-8.90	―	―	―	72.92%
SVA	44 Neutral	C$48.82M	-3.13	―	―	―	54.38%
MIR	42 Neutral	C$48.84M	-12.07	―	―	-41.70%	-35.42%

Medmira Corporate Events

MedMira Narrows Loss as New Syphilis Test Wins Approval and MiROQ Platform Advances

MedMira reported first-quarter fiscal 2026 results marked by Health Canada approval of its Reveal TP rapid syphilis antibody test, enabling nationwide deployment through provincial validations and complementing its existing HIV and dual HIV/TP products. The company advanced its Multiplo Complete Syphilis (TP/nTP) Antibody Test program, moving into a second phase of Canadian clinical trials following strong sensitivity and specificity data published in BMC Infectious Diseases, positioning the test as a tool to support antimicrobial stewardship and reduce healthcare costs. In parallel, MedMira is working with partners to accelerate commercialization of its MiROQ quantitative diagnostic platform, integrating AI for faster, more reliable diagnostics and broadening its future product and market reach. Financially, the quarter showed modest revenue of $54,208 and a narrowed net loss of $813,134 versus the prior year, driven largely by lower operating expenses, alongside a slight decline in assets and an increase in liabilities, underscoring the company’s continued investment phase in product development and regulatory advancement.

The most recent analyst rating on (TSE:MIR) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on Medmira stock, see the TSE:MIR Stock Forecast page.

MedMira Inc. Reports FY2025 Financial Results and Strategic Developments

MedMira Inc. reported its FY2025 financial results, highlighting significant product launches and regulatory approvals in Canada and the USA. Despite a net loss and increased operating expenses due to R&D and marketing activities, the company achieved milestones such as Health Canada approvals and VA and Federal listings in the USA, enhancing its market positioning and sales capabilities. The development of its MiRO Q technology, aimed at improving diagnostics, particularly in cancer, is expected to expand product offerings and market access, providing substantial value to the company.